A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant (START-DCD)
A Prospective, Multi-center, Single-arm, Interventional Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant in China
Sponsor: Sanofi
Listed as NCT03099122, this PHASE4 trial focuses on End-stage Renal Disease and remains completed. Sponsored by Sanofi, it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
May 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — May 2022 [monthly]
Completed PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jul 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jul 2019 [monthly]
Recruiting PHASE4
-
Aug 2018 — Apr 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE4
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .